Category: Epidarex Portfolio News
Crestwood, KY – July 15, 2015 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as key opinion leaders in the areas of immunology, pulmonology, ophthalmology and hematology….
Brighton, Sussex, May 20th 2015 – Enterprise Therapeutics Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. The funds are comprised of £2m by new investor, Imperial Innovations and…
Baltimore, MD, May 7, 2015 – Harpoon Medical, a medical device company focused on minimally invasive mitral valve repair, announced today that it has enrolled the initial three patients in an Early Feasibility Study of its repair system for the minimally invasive, beating-heart treatment of MR….
Glasgow, United Kingdom, April 13th 2015 – Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the…
Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions. In particular, the article discusses how the complement system plays a key role…
Brighton, Sussex, February 11th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug…
Crestwood, KY – February 10th 2015 – Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal…
By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…